Murray Stahl's GALT Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 49,226 shares of Galectin Therapeutics Inc. (GALT) worth $137,341, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in GALT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 30,000 shares. Largest reduction occurred in Q4 2023, reducing 2,258 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Galectin Therapeutics (GALT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Galectin Therapeutics (GALT) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2,258 | Reduce 4.39% | 49,226 | $2.79 |
| Q4 2025 | -2,258 | Reduce 4.20% | 51,484 | $4.16 |
| Q3 2025 | +2,258 | Add 4.39% | 53,742 | $4.23 |
| Q2 2025 | -2,258 | Reduce 4.20% | 51,484 | $2.11 |
| Q4 2024 | +2,258 | Add 4.39% | 53,742 | $1.29 |
| Q3 2024 | -2,258 | Reduce 4.20% | 51,484 | $2.75 |
| Q4 2023 | -2,258 | Reduce 4.03% | 53,742 | $1.66 |
| Q1 2023 | +30,000 | Add 115.38% | 56,000 | $2.10 |
| Q1 2022 | +2,000 | Add 8.33% | 26,000 | $1.62 |
| Q2 2021 | +24,000 | New Buy | 24,000 | $3.21 |
Murray Stahl's Galectin Therapeutics Investment FAQs
Murray Stahl first purchased Galectin Therapeutics Inc. (GALT) in Q2 2021, acquiring 24,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Galectin Therapeutics Inc. (GALT) for 20 quarters since Q2 2021.
Murray Stahl's largest addition to Galectin Therapeutics Inc. (GALT) was in Q1 2023, adding 56,000 shares worth $117,600.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 49,226 shares of Galectin Therapeutics Inc. (GALT), valued at approximately $137,341.
As of the Q1 2026 filing, Galectin Therapeutics Inc. (GALT) represents approximately 0.00% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Galectin Therapeutics Inc. (GALT) was 56,000 shares, as reported at the end of Q1 2023.